DexCom, Inc. (DXCM) on Decifer

Decifer ranks DXCM number 241 of 265 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 17% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 16% a year, profits grew 47% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• It trades about 69% above similar companies, and its growth does not yet back up that price.
• A valuation about 67 percent above peers blocks the path for 17 percent returns and 47 percent profit growth with no worldview role.

The current read

The evidence on DXCM lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full DXCM research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.